We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.3B
AUM Growth
+$177M
Cap. Flow
+$235M
Cap. Flow %
18.05%
Top 10 Hldgs %
40.67%
Holding
213
New
103
Increased
34
Reduced
21
Closed
43

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$47.9M
2
ABBV icon
AbbVie
ABBV
+$27.8M
3
JNJ icon
Johnson & Johnson
JNJ
+$18.7M
4
LPSN icon
LivePerson
LPSN
+$16.1M
5
AZN icon
AstraZeneca
AZN
+$13.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$40.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$26.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.8M
4
ZYME icon
Zymeworks
ZYME
+$11.6M
5
META icon
Meta Platforms (Facebook)
META
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 62.55%
2 Technology 7.69%
3 Industrials 4.91%
4 Financials 2.93%
5 Consumer Discretionary 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
26
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$10.3M 0.79%
+888,800
New +$10.2M
ICLN icon
27
PUT
iShares Global Clean Energy ETF
ICLN
$2.31B
$10.2M 0.78%
+420,000
New +$11.7M
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
$10.1M 0.78%
137,672
+106,372
+340% +$8.33M
CRIS icon
29
Curis
CRIS
$9.78M
$10M 0.77%
+2,215
New +$9.26M
ORTX
30
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.92M 0.76%
+136,656
New +$9.71M
KYMR icon
31
Kymera Therapeutics
KYMR
$8.51B
$9.62M 0.74%
247,527
+99,827
+68% +$6.01M
ALXO icon
32
ALX Oncology
ALXO
$261M
$9.61M 0.74%
130,351
-3,097
-2% -$244K
TEVA icon
33
Teva Pharmaceuticals
TEVA
$40.8B
$9.61M 0.74%
832,878
– –
FATE icon
34
Fate Therapeutics
FATE
$286M
$9.05M 0.69%
109,807
+27,807
+34% +$2.66M
VTGN icon
35
VistaGen Therapeutics
VTGN
$9.89M
$8.9M 0.68%
139,239
+48,406
+53% +$3.23M
ZLAB icon
36
Zai Lab
ZLAB
$2.06B
$8.78M 0.67%
+65,788
New +$10.2M
NICE icon
37
Nice
NICE
$5.79B
$8.61M 0.66%
39,481
-35,000
-47% -$8.76M
AMZN icon
38
Amazon
AMZN
$2.92T
$8.54M 0.66%
55,220
+14,000
+34% +$2.22M
PRGO icon
39
CALL
Perrigo
PRGO
$1.4B
$8.5M 0.65%
+210,000
New +$9.01M
ONTO icon
40
Onto Innovation
ONTO
$12.9B
$8.21M 0.63%
+125,000
New +$7.44M
TLT icon
41
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
$8.13M 0.62%
+60,000
New +$8.7M
SGTX
42
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$8.07M 0.62%
27,865
-15,786
-36% -$6.28M
AFMD
43
DELISTED
Affimed
AFMD
$8.06M 0.62%
+101,897
New +$6.62M
BOLT icon
44
Bolt Biotherapeutics
BOLT
$7.67M
$7.93M 0.61%
+12,050
New +$7.84M
RPTX
45
DELISTED
Repare Therapeutics
RPTX
$7.61M 0.58%
248,100
+23,800
+11% +$808K
ZNTL icon
46
Zentalis Pharmaceuticals
ZNTL
$337M
$7.6M 0.58%
175,140
-15,656
-8% -$674K
PNT
47
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.57M 0.58%
720,000
+700,000
+3,500% +$9.49M
ATER icon
48
Aterian
ATER
$4.45M
$7.41M 0.57%
+20,918
New +$8.06M
CSTE icon
49
Caesarstone
CSTE
$72.3M
$7.35M 0.56%
+535,148
New +$7.08M
SPRY icon
50
ARS Pharmaceuticals
SPRY
$509M
$7.32M 0.56%
167,799
-6,462
-4% -$306K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2021 Portfolio in Review

As of Q1 2021, Sphera Funds Management held 213 positions worth $1.3B, up 16% from $1.13B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management deployed $235M of net new capital in Q1 2021, opening 103 new positions and adding to 34 existing holdings. Its largest new stake was Sanofi: 997,900 shares worth $49.4M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 68% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $26.4M trimmed.

  • Sphera Funds Management's largest Q1 2021 buy was Sanofi: 997,900 shares worth $49.4M.
  • Sphera Funds Management added most to AbbVie in Q1 2021, an estimated $27.8M increase.
  • Sphera Funds Management's biggest Q1 2021 reduction was Bristol-Myers Squibb, cutting an estimated $26.4M.
  • Sphera Funds Management fully exited Novartis in Q1 2021, selling an estimated $40.5M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.3B portfolio in Q1 2021.
  • Sphera Funds Management opened 103 new positions and closed 43 in Q1 2021.
  • Sphera Funds Management's portfolio value rose 16% quarter-over-quarter to $1.3B.

Based on Sphera Funds Management's 13F filing for Q1 2021, filed 17 May 2021.